tetano
Editor, Senior Moderator
Vaccine. 2019 Jul 31. pii: S0264-410X(19)30997-1. doi: 10.1016/j.vaccine.2019.07.076. [Epub ahead of print]
[h=1]Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.[/h] Noh JY[SUP]1[/SUP], Jang YS[SUP]2[/SUP], Lee SN[SUP]2[/SUP], Choi MJ[SUP]1[/SUP], Yoon JG[SUP]2[/SUP], Yu DH[SUP]2[/SUP], Song JY[SUP]1[/SUP], Cheong HJ[SUP]1[/SUP], Kim WJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a major medically attended respiratory illness. The impact of influenza on morbidity and mortality is particularly high in the elderly. Immunosenescence attenuates the immune response of influenza vaccine in the elderly. High-dose influenza vaccine contains 60 μg of hemagglutinin per strain, four times more compared with standard-dose (SD) influenza vaccine. This study is a phase I clinical trial investigating the immunogenicity and safety of the GC3114, high-dose, quadrivalent inactivated influenza vaccine (HD-QIV) in healthy adults aged 19-64 years during the 2017-2018 season. Seroprotection rates of HD-QIV were 100.0% for A/H1N1, 96.67% for A/H3N2, 83.33% for B/Yamagata, and 96.67% for B/Victoria. Seroconversion rate for A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 86.67%, 90.0%, 53.33%, and 53.33%, respectively, in the HD-QIV group. The post-/pre-vaccination geometric mean titer ratio (GMTR) was 15.28 for A/H1N1, 8.19 for A/H3N2, 3.56 for B/Yamagata, and 3.03 for B/Victoria in the HD-QIV group. Seroconversion rate and post-/pre-vaccination GMTR for A/H3N2 were significantly higher in the HD-QIV group than in the SD-QIV group (control). No serious adverse events were reported. In conclusion, GC3114 was safe, well-tolerated, and immunogenic in healthy adults. Clinical Trials Identifier: NCT03357263.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Frail elderly; Influenza vaccines; Influenza, human
PMID: 31377075 DOI: 10.1016/j.vaccine.2019.07.076
[h=1]Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.[/h] Noh JY[SUP]1[/SUP], Jang YS[SUP]2[/SUP], Lee SN[SUP]2[/SUP], Choi MJ[SUP]1[/SUP], Yoon JG[SUP]2[/SUP], Yu DH[SUP]2[/SUP], Song JY[SUP]1[/SUP], Cheong HJ[SUP]1[/SUP], Kim WJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a major medically attended respiratory illness. The impact of influenza on morbidity and mortality is particularly high in the elderly. Immunosenescence attenuates the immune response of influenza vaccine in the elderly. High-dose influenza vaccine contains 60 μg of hemagglutinin per strain, four times more compared with standard-dose (SD) influenza vaccine. This study is a phase I clinical trial investigating the immunogenicity and safety of the GC3114, high-dose, quadrivalent inactivated influenza vaccine (HD-QIV) in healthy adults aged 19-64 years during the 2017-2018 season. Seroprotection rates of HD-QIV were 100.0% for A/H1N1, 96.67% for A/H3N2, 83.33% for B/Yamagata, and 96.67% for B/Victoria. Seroconversion rate for A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 86.67%, 90.0%, 53.33%, and 53.33%, respectively, in the HD-QIV group. The post-/pre-vaccination geometric mean titer ratio (GMTR) was 15.28 for A/H1N1, 8.19 for A/H3N2, 3.56 for B/Yamagata, and 3.03 for B/Victoria in the HD-QIV group. Seroconversion rate and post-/pre-vaccination GMTR for A/H3N2 were significantly higher in the HD-QIV group than in the SD-QIV group (control). No serious adverse events were reported. In conclusion, GC3114 was safe, well-tolerated, and immunogenic in healthy adults. Clinical Trials Identifier: NCT03357263.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Frail elderly; Influenza vaccines; Influenza, human
PMID: 31377075 DOI: 10.1016/j.vaccine.2019.07.076